We are live on ! Find out more
BBOT

BridgeBio Oncology
BBOT

34 hedge funds and large institutions have $178M invested in BridgeBio Oncology in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

10% more funds holding

Funds holding: 31 → 34 (+3)

1.22% more ownership

Funds ownership: 87.19% → 88.41% (+1.2%)

5% less capital invested

Capital invested by funds: $186M → $178M (-$8.71M)

Holders
34
Holders Change
+3
Holders Change %
+9.68%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
7
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WRBC
W.R. Berkley Corp
Connecticut
+$4.81M
2
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$3.31M
3
SCM
Shaolin Capital Management
Florida
+$3.16M
4
CS
Clear Street
New York
+$2.22M
5
Creative Planning
Creative Planning
Kansas
+$2.16M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$4.5M
2
FBCM
Fort Baker Capital Management
California
-$4.23M
3
GPP
Great Point Partners
Connecticut
-$3.72M
4
Millennium Management
Millennium Management
New York
-$2.15M
5
Two Sigma Investments
Two Sigma Investments
New York
-$2.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$30.9M – – –
BlackRock
2
BlackRock
New York
$15.9M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$15.2M +$165K +15,241 +1%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$14.9M – – –
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$11.4M – – –
Millennium Management
6
Millennium Management
New York
$9.53M -$2.15M -199,131 -18%
SC
7
Sculptor Capital
New York
$8.5M – – –
SCM
8
Silverarc Capital Management
Massachusetts
$6.51M – – –
FCM
9
Farallon Capital Management
California
$6.39M – – –
HCI
10
Harraden Circle Investments
New York
$6.05M +$468K +43,296 +8%
WRBC
11
W.R. Berkley Corp
Connecticut
$4.73M +$4.81M +445,195 New
Toronto Dominion Bank
12
Toronto Dominion Bank
Ontario, Canada
$4.72M +$3.31M +306,377 +222%
ACM
13
ADAR1 Capital Management
Texas
$4.7M -$293K -27,114 -6%
PA
14
Perceptive Advisors
New York
$4.23M – – –
DAM
15
Decagon Asset Management
United Kingdom
$3.7M +$1.18M +108,820 +45%
SC
16
Stempoint Capital
New York
$3.29M +$1.24M +114,912 +57%
LCM
17
Laurion Capital Management
New York
$3.19M – – –
SCM
18
Shaolin Capital Management
Florida
$3.1M +$3.16M +292,338 New
OCA
19
Octagon Capital Advisors
New York
$2.66M – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$2.24M +$626K +57,909 +38%
CS
21
Clear Street
New York
$2.18M +$2.22M +205,666 New
Creative Planning
22
Creative Planning
Kansas
$2.12M +$2.16M +200,000 New
ACP
23
Acuta Capital Partners
California
$1.99M – – –
Wellington Management Group
24
Wellington Management Group
Massachusetts
$1.97M – – –
TD Asset Management
25
TD Asset Management
Ontario, Canada
$1.54M – – –
1
2

BBOT Hedge Fund Activity: Q2 2025 in Review

34 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q2 2025, worth a combined $178M — down 4.7% from $186M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BBOT positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was W.R. Berkley Corp, opening a new position worth an estimated $4.81M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $4.5M sold.

  • 34 institutional investors held BridgeBio Oncology (BBOT) as of Q2 2025, up from 31 in Q1 2025.
  • Funds reported $178M of BridgeBio Oncology stock for Q2 2025, down 4.7% quarter-over-quarter.
  • 7 funds opened new BridgeBio Oncology positions in Q2 2025 and 4 closed out, a net change of +3 holders.
  • The largest BridgeBio Oncology buyer in Q2 2025 was W.R. Berkley Corp, an estimated $4.81M added.
  • The largest BridgeBio Oncology seller in Q2 2025 was T. Rowe Price Investment Management, an estimated $4.5M sold.

Based on aggregated 13F filings for Q2 2025.